SCHEMBL5114310

SCHEMBL5114310

C#Cc1ccsc1-c1nc2cnccn2c1NC(C)=O.c1cc2cc-2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GAA P10253 9/20 0.40
MAPT P10636 5/20 0.40
KDM4E B2RXH2 7/20 0.38
ALDH1A1 P00352 6/20 0.38
HPGD P15428 5/20 0.38
BRAF P15056 2/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 2/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127803 0.90 SYK (0.39) SYKGAAMAPTKDM4EALDH1A1
SCHEMBL5113515 0.89 GAA (0.41) SYKGAAMAPTKDM4EALDH1A1
SCHEMBL5122885 0.89 HSD17B10 (0.46) SYKGAAMAPTKDM4EBRAF
SCHEMBL5121542 0.86 GAA (0.43) SYKGAAMAPTKDM4EALDH1A1
SCHEMBL5115036 0.85 GAA (0.49) SYKNPC1RAB9AGAAMAPT
SCHEMBL5121924 0.85 MAPT (0.42) SYKNPC1RAB9AGAAMAPT
SCHEMBL5118759 0.85 CDK9 (0.41) SYKGAAMAPTKDM4EALDH1A1
SCHEMBL5127406 0.85 SALL4 (0.46) GAAKDM4EALDH1A1BRAFLMNA
SCHEMBL5129311 0.84 PLAU (0.42) GAAMAPTKDM4EALDH1A1HPGD
SCHEMBL5121032 0.83 CDK9 (0.41) SYKGAAMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS SYK 2488/4885NPC1 219/4885RAB9A 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.